Informing optimal dosing of the future antimalarial, artemether-lumefantrine plus amodiaquine, in key neglected target populations of children with severe acute malnutrition and adults living with HIV
Active Project Grant Awarded Last action
- Award ID
- K43TW012801
- Recipient
-
Kamuzu University Of Health Sciences UEI E7PXR3Q3LWJ4
- Awarding agency
-
Fogarty International Center
National Institutes of Health, Department of Health and Human Services
- Obligated
- $326,382
Award facts
- Assistance listing
- 93.989 International Research and Research Training
- Completion date 44% complete
- Place of performance
- Malawi
Award details come from USAspending.gov.
Description
- Abstract
- This award will allow DR clifford george banda to characterise the pharmacokinetic and safety profiles of two long-acting artemisinin partner drugs, lumefantrine and amodiaquine and their active metabolites when administered as artemether-lumefantrine plus amodiaquine (alaq) in african young children with uncomplicated severe acute malnutrition as well as adults living with HIV and on dolutegravir-based antiretroviral therapy. DR banda, malawi's first medical specialist in clinical pharmacology and therapeutics, will further his career development by;1) gaining skills in early phase clinical trial design and conduct in complex subpopulations; 2) consolidating skills in clinical translation of quantitative pharmacology (population pharmacokinetic-pharmacodynamic modelling) to inform dose optimisation of antimalarials in the two key target subgroups of children with severe acute malnutrition and adults living with HIV; and 3) strengthening his clinical and research leadership skills to allow transition into research career independence. In the proposed project work, he hypothesises that severe acute malnutrition is associated with reduced absorption and subsequent bioavailability of lumefantrine, amodiaquine and their active metabolites. Consequently, the attained concentrations would be insufficient to treat and prevent malaria recurrence. He will study the effect of uncomplicated severe acute malnutrition on lumefantrine and amodiaquine exposure. Furthermore, there are concerns about a potential reduction of dolutegravir exposure when amodiaquine is CO-administered with dolutegravir-based antiretroviral therapy, DR banda will characterise the effect of alaq on dolutegravir overall exposure in adults living with HIV. This evidence is needed to inform the optimal dosing of the promising triple antimalarial combination, alaq, in these two subpopulations. IT would support the world health organisation's strategy for responding to antimalarial resistance in africa by identifying innovative ways to combine and repurpose existing antimalarial therapies as a tool to delay antimalarial resistance while awaiting the development and licensing of novel non-artemisinin-based combination therapies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $108,662 | |
| Amendment | $108,804 | |
| Original award | $108,916 |
Quick answers
Who received award K43TW012801?
K43TW012801 was awarded to Kamuzu University Of Health Sciences by Fogarty International Center (National Institutes of Health) on September 1, 2024.
How much is award K43TW012801 worth?
$326,382 has been obligated on K43TW012801.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award